Evolus Inc (EOLS NASDAQ) stock market data APIs
$7.9549
0.03(0.4%)
as of September 14, 2026
Try our APIs with
free plan!
Evolus Inc Financial Data Overview
Price chart is built with
Anychart
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Prev. Close
7.9549
Open
7.9606
High
8.304
Low
7.9231
52 wk Range
3.86-9.31
Market Cap
524 M
Shares Outstanding
66 050 K
Revenue
316 M
EPS
-0.09
Beta
1.429
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Evolus Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Evolus Inc data using free add-ons & libraries
Get Evolus Inc Fundamental Data
Evolus Inc Fundamental data includes:
- Net Revenue: 316 M
- EBITDA: -12 774 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Evolus Inc News
New
Evolus (EOLS) Notches A Profit Milestone While Betting Big On The Future
On August 5, Evolus (NASDAQ:EOLS) reported second-quarter 2026 results that showed the company finally translating years of growth into the bottom line. Global net revenue reached $84.1 million, up 21...
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
NEW YORK, Sept. 1, 2026 /PRNewswire/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-r...
Telix Appoints David Gill as Chair
Telix Pharmaceuticals Limited David Gill appointed Chair of the Telix Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would bec...
Following Heightened Competition from Botox, Xeomin, and Long-Acting Daxxify, New Study Evaluates Dysport (abobotulinumtoxinA) Revenue Trajectory Through 2034
Company Logo As the global neurotoxin market expands across cosmetic facial aesthetics and neurological therapeutic applications, Dysport (abobotulinumtoxinA)—developed and commercialized by Ipsen ...
Get Evolus Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
